Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Keep Your Eye On Oncomed Pharmaceuticals

|Includes: BAYZF, CELG, GSK, OncoMed Pharmaceuticals, Inc (OMED)

Keep your eyes on shares of OMED heading into next week. I believe the company to have its own idiosyncratic risk/reward profile in a market I believe will be pulling back significantly.

(See my recent piece here, seekingalpha.com/article/2674015-sell-off-coming-prepare-accordingly)

Data will be released next week for preclinical trials and 2015 is expected to be a year full of advanced trial data.

I am long shares of OMED.

  • development stage biotech firm w/ approx. $620m market cap
  • big name partners in Celgene (NASDAQ:CELG), Bayer (BAYSY) and GlaxoSmithKline (NYSE:GSK)
  • raised year end cash balance to over $225 million
  • good revenue growth through milestone payments.
  • costs appear under control, particularly on the SG&A side
  • broad pipeline and upcoming data releases
  • risk/reward favorable at these levels

Check out my charts and Oncomed's pipeline below.

Cheers!

Disclosure: The author is long OMED.

Additional disclosure: The author wrote this article themselves, and it expresses their own opinions. The article should not be considered a recommendation to buy or sell or investment advice. The article is intended to inform the reader of potential investment idea. Personal due diligence is always recommended.